Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK.
Campbell C., Wang T., Smith DA., Freeman O., Noble T., Várnai KA., Harris S., Salih H., Roadknight G., Little S., Glampson B., Mercuri L., Papadimitriou D., Jones CR., Taylor V., Chaudhry A., Phan H., Borca F., Olza J., Warricker F., Romão L., Ramlakhan D., English L., Klenerman P., Andersson MI., Collier J., Nastouli E., Khakoo SI., Gelson W., Cooke GS., Woods K., Davies J., Barnes E., Matthews PC.
BackgroundTo determine the impact of the COVID-19 pandemic on the population with chronic Hepatitis B virus (HBV) infection under hospital follow-up in the UK, we quantified the coverage and frequency of measurements of biomarkers used for routine surveillance (alanine transferase [ALT] and HBV viral load).MethodsWe used anonymized electronic health record data from the National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) pipeline representing five UK National Health Service (NHS) Trusts.ResultsWe report significant reductions in surveillance of both biomarkers during the pandemic compared to pre-COVID-19 years, both in terms of the proportion of patients who had ≥1 measurement annually, and the mean number of measurements per patient.ConclusionsThese results demonstrate the real-time utility of HIC data in monitoring health-care provision, and support interventions to provide catch-up services to minimise the impact of the pandemic. Further investigation is required to determine whether these disruptions will be associated with increased rates of adverse chronic HBV outcomes.